MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (AMEX:OPK) announced today that it has begun treating patients in a clinical trial of its Aquashunt™, a device for the treatment of refractory open angle glaucoma. The study, at two academic departments of ophthalmology, is designed to assess the safety and efficacy of the Aquashunt™ and will enroll up to 20 patients with significantly impaired visual acuity.
